Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasted to Earn Q2 2024 Earnings of ($0.23) Per Share

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Equities research analysts at Zacks Research increased their Q2 2024 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research note issued to investors on Tuesday, May 21st. Zacks Research analyst K. Das now anticipates that the biopharmaceutical company will post earnings of ($0.23) per share for the quarter, up from their prior estimate of ($0.25). The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.05) per share. Zacks Research also issued estimates for Esperion Therapeutics’ Q4 2024 earnings at ($0.17) EPS, FY2024 earnings at ($0.23) EPS, Q1 2025 earnings at ($0.11) EPS, Q2 2025 earnings at ($0.04) EPS, Q3 2025 earnings at ($0.02) EPS, FY2025 earnings at ($0.08) EPS, Q1 2026 earnings at ($0.01) EPS and FY2026 earnings at $0.32 EPS.

Several other equities analysts have also recently commented on ESPR. Needham & Company LLC reissued a “buy” rating and set a $8.00 target price on shares of Esperion Therapeutics in a research report on Tuesday, May 7th. StockNews.com cut Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, May 17th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of Esperion Therapeutics in a research report on Tuesday. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, Esperion Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $9.33.

Esperion Therapeutics Price Performance

Shares of ESPR stock opened at $2.13 on Thursday. Esperion Therapeutics has a one year low of $0.70 and a one year high of $3.40. The company has a market cap of $403.55 million, a P/E ratio of -2.14 and a beta of 0.89. The firm has a 50-day moving average of $2.31 and a 200-day moving average of $2.17.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.03. The company had revenue of $32.25 million for the quarter, compared to the consensus estimate of $26.84 million. During the same quarter last year, the company posted ($0.76) EPS.

Institutional Investors Weigh In On Esperion Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Bayesian Capital Management LP bought a new position in Esperion Therapeutics during the first quarter worth about $137,000. Bellevue Group AG lifted its stake in shares of Esperion Therapeutics by 136.5% during the 1st quarter. Bellevue Group AG now owns 9,944,064 shares of the biopharmaceutical company’s stock valued at $26,650,000 after buying an additional 5,739,800 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Esperion Therapeutics by 71.8% in the 1st quarter. Vanguard Group Inc. now owns 8,826,546 shares of the biopharmaceutical company’s stock worth $23,655,000 after buying an additional 3,688,796 shares during the period. Tocqueville Asset Management L.P. purchased a new position in Esperion Therapeutics in the 1st quarter valued at approximately $107,000. Finally, State Board of Administration of Florida Retirement System purchased a new position in Esperion Therapeutics in the 1st quarter valued at approximately $50,000. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.